Patents by Inventor Roger Tung

Roger Tung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200050102
    Abstract: Examples of a multiple-mask multiple-exposure lithographic technique and suitable masks are provided herein. In some examples, a photomask includes a die area and a stitching region disposed adjacent to the die area and along a boundary of the photomask. The stitching region includes a mask feature for forming an integrated circuit feature and an alignment mark for in-chip overlay measurement.
    Type: Application
    Filed: October 21, 2019
    Publication date: February 13, 2020
    Inventors: Peter Yu, Chih-Tung Hsu, Kevin Wang, Chih-Chia Hu, Roger Chen
  • Publication number: 20190225607
    Abstract: This invention relates to deuterated forms of venetoclax, and pharmaceutically acceptable salts thereof. Certain aspects of this invention also provide pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier. Certain aspects of the present invention also provide the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of the anti-apoptotic activity of the B-cell lymphoma 2 (Bcl-2) protein.
    Type: Application
    Filed: June 30, 2017
    Publication date: July 25, 2019
    Inventor: Roger Tung, Ph.D.
  • Publication number: 20180327809
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?i receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: December 12, 2017
    Publication date: November 15, 2018
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Patent number: 9314440
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: April 19, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Patent number: 9273009
    Abstract: This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment: as described herein. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a selective T-type calcium channel blocker.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: March 1, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger Tung, Craig E. Masse, Julie F. Liu
  • Publication number: 20150299166
    Abstract: This invention relates to novel ALK inhibitors of Formula I: as defined in the specification, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering ALK inhibitors.
    Type: Application
    Filed: December 19, 2013
    Publication date: October 22, 2015
    Inventor: Roger TUNG
  • Publication number: 20150299170
    Abstract: This invention relates to novel fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).
    Type: Application
    Filed: November 20, 2013
    Publication date: October 22, 2015
    Inventors: Bhaumik A. Pandya, Roger Tung
  • Patent number: 9145390
    Abstract: This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: September 29, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Bhaumik Pandya, Craig E. Masse, Ian Robert Silverman, Roger Tung
  • Patent number: 9133137
    Abstract: This invention relates to novel quinazoline derivatives, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by inhibiting cell surface tyrosine receptor kinases.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: September 15, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Patent number: 9107922
    Abstract: This disclosure relates to novel HIV integrase inhibitors their derivatives, pharmaceutically acceptable salts thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating HIV infections.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: August 18, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Patent number: 9072711
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: July 7, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Publication number: 20150166601
    Abstract: The present invention in one embodiment provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula (I) are as defined in the specification. The compound of Formula (I) is useful for the treatment of diseases such as a disease selected from the group consisting of multiple myeloma, solid tumors, lymphoma, and leukemia.
    Type: Application
    Filed: July 12, 2013
    Publication date: June 18, 2015
    Applicant: CONCERT PHARMACEUTICALS INC.
    Inventors: Adam Morgan, Roger Tung
  • Patent number: 9045453
    Abstract: This invention relates to novel substituted dioxopiperidinyl phthalimide derivatives and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an immunomodulatory agent.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: June 2, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Patent number: 8993570
    Abstract: This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an ?1-GABAA receptor antagonist or an ?2- and/or an ?3-GABAA receptor partial agonist.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: March 31, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Scott L. Harbeson, Roger Tung, Julie F. Liu
  • Patent number: 8889687
    Abstract: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: November 18, 2014
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Roger Tung, Scott L. Harbeson
  • Publication number: 20140329846
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventor: Roger Tung
  • Patent number: 8796267
    Abstract: This invention relates to novel N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide derivatives, their acceptable acid addition salts, solvates and hydrates. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antimicrobial agents.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: August 5, 2014
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger Tung, Scott Harbeson
  • Patent number: 8759383
    Abstract: The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: June 24, 2014
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Patent number: 8748450
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: June 10, 2014
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Publication number: 20140155444
    Abstract: This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment: as described herein. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a selective T-type calcium channel blocker.
    Type: Application
    Filed: October 21, 2013
    Publication date: June 5, 2014
    Applicant: Concert Pharmaceuticals Inc.
    Inventors: Roger Tung, Craig E. Masse, Bhaumik A. Pandya